{"id":"87bad202-c036-57dd-9e94-e3d08c8c9c5b","stable_key":"0a5134ca-a214-59b8-8017-f89b299ace92:cerivastatin-exposure-and-rhabdomyolysis-risk","predicate":"increases","statement":"Concomitant use of gemfibrozil with statins, and particularly with cerivastatin, increases the risk of rhabdomyolysis, and this study was undertaken because the mechanism of that potentially fatal interaction was unclear.","claim_class":"mechanistic","status":"source_derived_draft","evidence_grade":"ungraded","direction":"positive","is_public":true,"mechanism_event_id":"ef52d8c9-70f0-5f40-bbd5-1e56565889a8","mechanism_event_label":"Concomitant use of gemfibrozil with statins, and particularly with cerivastatin, increases the risk of rhabdomyolysis, and this study was undertaken because the mechanism of that potentially fatal interaction was unclear.","subject":{"id":"45564888-eb93-5ac1-956f-d362732fc9cc","slug":"cerivastatin-plasma-exposure","display_name":"Plasma cerivastatin exposure","entity_type_key":"cellular_process"},"object":{"id":"6d822dfd-c22c-594d-9660-a539e8b22759","slug":"statin-muscle-pain","display_name":"Statin-associated muscle pain","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"ef52d8c9-70f0-5f40-bbd5-1e56565889a8","stable_key":"0a5134ca-a214-59b8-8017-f89b299ace92:cerivastatin-exposure-and-rhabdomyolysis-risk-event","event_type":"observed_relationship","label":"Concomitant use of gemfibrozil with statins, and particularly with cerivastatin, increases the risk of rhabdomyolysis, and this study was undertaken because the mechanism of that potentially fatal interaction was unclear.","description":"Concomitant use of gemfibrozil with statins, and particularly with cerivastatin, increases the risk of rhabdomyolysis, and this study was undertaken because the mechanism of that potentially fatal interaction was unclear.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"45564888-eb93-5ac1-956f-d362732fc9cc","slug":"cerivastatin-plasma-exposure","display_name":"Plasma cerivastatin exposure","entity_type_key":"cellular_process"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"6d822dfd-c22c-594d-9660-a539e8b22759","slug":"statin-muscle-pain","display_name":"Statin-associated muscle pain","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"be172818-3b91-5a27-8657-a620397442da","slug":"gemfibrozil","display_name":"Gemfibrozil","entity_type_key":"drug"},"role":"context_participant","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""},{"entity":{"id":"ade21be6-666e-59a9-8b89-06996f86551f","slug":"cerivastatin","display_name":"Cerivastatin","entity_type_key":"small_molecule"},"role":"context_participant","stoichiometry":null,"state_label":"","sequence_order":3,"notes":""}]},"contexts":[{"dimension":"duration","value_text":"Not applicable","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"evidence_access","value_text":"Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Stated as the background to a 10-volunteer pharmacokinetic study","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"Gemfibrozil with cerivastatin","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"This is the study's framing of an established clinical association rather than a measurement made in it; no muscle outcome was recorded in the ten volunteers.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"organism","value_text":"Stated as the background to a 10-volunteer pharmacokinetic study","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"Concomitant use of gemfibrozil with statins, and particularly with cerivastatin, increases the risk of rhabdomyolysis, and this study was undertaken because the mechanism of that potentially fatal interaction was unclear.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Gemfibrozil greatly increases plasma concentrations of cerivastatin. (2002). https://pubmed.ncbi.nlm.nih.gov/12496749/ DOI: 10.1067/mcp.2002.128469","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"route","value_text":"Oral","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue","value_text":"Skeletal muscle injury risk during combined treatment","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"2f37def0-59bb-5173-9429-c6d295d87bb5","evidence_kind":"source_excerpt","locator":"Lines 57-66","start_line":57,"end_line":66,"excerpt":"## cerivastatin-exposure-and-rhabdomyolysis-risk\nConcomitant use of gemfibrozil with statins, and particularly with cerivastatin, increases the risk of rhabdomyolysis, and this study was undertaken because the mechanism of that potentially fatal interaction was unclear.\nModel/species: Stated as the background to a 10-volunteer pharmacokinetic study\nTissue/system: Skeletal muscle injury risk during combined treatment\nExposure: Gemfibrozil with cerivastatin\nRoute: Oral\nDuration: Not applicable\nLimits: This is the study's framing of an established clinical association rather than a measurement made in it; no muscle outcome was recorded in the ten volunteers.\nPrimary reference: Gemfibrozil greatly increases plasma concentrations of cerivastatin. (2002). https://pubmed.ncbi.nlm.nih.gov/12496749/ DOI: 10.1067/mcp.2002.128469\nAccess: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.","model_system":"","directness":"reported_statement","verification_status":"source_derived_draft","notes":"","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"6e42a53a-5f31-5a81-87ba-a3edc49aface","stable_key":"import-0a5134ca-a214-59b8-8017-f89b299ace92","title":"Statin plasma exposure and muscle injury: dose randomisation and a drug interaction (2026-09-22)","document_type":"imported_text","citation_label":"Original AI-assisted curation of three primary studies resolved by PubMed title search and cross-checked against live PubMed metadata. Two share a research group with the OATP1B1 collection and are recorded as one line of evidence with it. Study-specific doses, effect sizes and limitations retained. Not publisher full text.","file_path":"","sha256":"33f81004d0b40ff01b3cc13113ba2991833a171a7a535fdf1c2d3c015f9f7b1c","revision_id":"3ccfa03e-b7ed-5569-9e22-af3e5de65955","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}